Results 301 to 310 of about 232,884 (341)

Cardiovascular Health in Women—Across the Lifespan

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Cardiovascular disease (CVD) remains the leading cause of mortality and morbidity among women worldwide. However, CVD continues to be perceived as a predominantly male issue. CVD in women therefore remains understudied, underrecognized and undertreated.
Jaya Chandrasekhar   +5 more
wiley   +1 more source

Increased Salt-Sensitive Blood Pressure in Women vs Men: Is Relative Hyperaldosteronism the Mechanism?

open access: yesJ Clin Endocrinol Metab
Caliskan Guzelce E   +8 more
europepmc   +1 more source

Effect of Pituitary-Target Gland Axis on RAAS in the Context of COVID-19. [PDF]

open access: yesInt J Med Sci
Wu B   +7 more
europepmc   +1 more source

Mass Spectrometric Measurements of 11‐Deoxycortisol, Androstenedione and Dehydroepiandrosterone Are Superior to Cortisol to Assess Selectivity of Non‐Stimulated Adrenal Vein Sampling

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Objective Successful adrenal venous sampling (AVS) is traditionally assessed using the ratio of cortisol in adrenal to peripheral venous plasma to calculate the selectivity index. With mass spectrometry other steroids can be simultaneously measured that may improve numbers of apparent successful sampling procedures.
Francesco Alessi   +14 more
wiley   +1 more source

Impact of the era of diabetes onset in a national care system on the prevalence of retinopathy and microalbuminuria in people living with type 1 diabetes 15 years post‐diagnosis: A cross‐sectional, real‐world observational study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This study investigates the impact of the era of diabetes onset on the prevalence of diabetic retinopathy and albuminuria 15 years post‐diagnosis in people living with type 1 diabetes (T1D) within a national healthcare system offering structured multidisciplinary endocrinology care.
Astrid Lavens   +8 more
wiley   +1 more source

Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real‐world settings.
Kim G. Smolderen   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy